A phase I, first‐in‐human, randomized dose‐escalation study of anti‐activated factor XII monoclonal antibody garadacimab

Factor XII (FXII) is the principal initiator of the plasma contact system and has proinflammatory and prothrombotic activities. This single‐center, first‐in‐human phase I study aimed to assess the safety and tolerability of single escalating doses of garadacimab, a monoclonal antibody that specifica...

Descripción completa

Detalles Bibliográficos
Autores principales: McKenzie, Andrew, Roberts, Anthony, Malandkar, Sourabh, Feuersenger, Henrike, Panousis, Con, Pawaskar, Dipti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8932690/
https://www.ncbi.nlm.nih.gov/pubmed/34859955
http://dx.doi.org/10.1111/cts.13180

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8932690/
https://www.ncbi.nlm.nih.gov/pubmed/34859955
http://dx.doi.org/10.1111/cts.13180

Ejemplares similares